DYN · NASDAQ · Biotechnology

Dyne Therapeutics

Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.

$25.07
After-hours close−0.01 (−0.04%)
At close$25.08(−3.87%)
DateEstimateReportedSurprise
Nov 2026−$0.84
Jul 2026−$0.75−$1.08−44.2%
May 2026−$0.77−$0.73+5.5%
Mar 2026−$0.74−$0.76−2.7%
Nov 2025−$0.81−$0.76+6.2%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Jul 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Oct 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Sep 2020
Jun 2020
Dec 2019
Sep 2019
Jun 2019
Mar 2019
Feb 2018
Nov 2017
Aug 2017
May 2017
Feb 2017
Nov 2016
Aug 2016
May 2016
Feb 2016
Nov 2015
Aug 2015
May 2015
Feb 2015
Nov 2014
Aug 2014
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Nov 4, 2026−$0.84
Jul 30, 2026−$0.75−$1.08−44.2%
May 11, 2026−$0.77−$0.73+5.5%
Mar 2, 2026−$0.74−$0.76−2.7%
Nov 5, 2025−$0.81−$0.76+6.2%

The latest year is open to everyone — the 41 quarters behind it read with an account.

Sign in
Jul 28, 2025
May 8, 2025
Feb 27, 2025
Nov 12, 2024
Aug 12, 2024
May 2, 2024
Mar 5, 2024
Oct 30, 2023
Aug 3, 2023
May 11, 2023
Mar 2, 2023
Nov 3, 2022
Aug 4, 2022
May 2, 2022
Mar 10, 2022
Nov 4, 2021
Aug 5, 2021
May 6, 2021
Mar 4, 2021
Nov 5, 2020
Sep 17, 2020
Jun 30, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Feb 22, 2018
Nov 1, 2017
Aug 4, 2017
May 5, 2017
Feb 24, 2017
Nov 2, 2016
Aug 4, 2016
May 4, 2016
Feb 25, 2016
Nov 5, 2015
Aug 7, 2015
May 7, 2015
Feb 25, 2015
Nov 6, 2014
Aug 7, 2014